Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population

International Journal of Molecular Medicine

Volumn 21, Issue 3, 2008, Pages 387-395

  Reiche, Edna Maria Vissoci ^a   Bonametti, Ana Maria ^a   Morimoto, Helena Kaminami ^a   Morimoto, Arilson Akira ^a,b   Wiechemann, Susana Lilian ^a   Matsuo, Tiemi ^a   Reiche, Fernando Vissoci ^a   Vogler, Ingridt Hildegard ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b Integrated Center of Infectious Diseases   (Brazil)

Author keywords

AIDS; Brazil; Co infection; Hepatitis C; Hepatitis C virus; Human immunodeficiency virus type 1

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS C ANTIBODY; HUMAN T CELL LEUKEMIA VIRUS ANTIBODY; VIRUS RNA;

ADULT; AGE; AGED; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; SEXUALLY TRANSMITTED DISEASE; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; SUPERINFECTION; TREATMENT OUTCOME; VENEREAL DISEASE REACTION TEST; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; BRAZIL; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RNA, VIRAL; SURVIVAL ANALYSIS;

EID: 40249090286     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Rockstroh JK and Spengler U: HIV and hepatitis C virus co-infection. Lancet Infect Dis 4: 437-444, 2004.
2. Shepard CW, Lyn F and Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567, 2005.
3. Mendes-Corrêa MC, Barone AA and Guastini C: Hepatitis C virus seroprevalence and risk factors among patients with HIV infection. Rev Inst Med Trop Sao Paulo 43: 15-19, 2001.
4. Martins RMB, Porto SOB, Vanderborght BOM, et al: Short report: prevalence of hepatitis C viral antibody among Brazilian children, adolescents, and street youths. Am J Trop Med Hyg 53: 654-655, 1995.
5. Silva L, Paraná R, Mota E, et al: Prevalence of hepatitis C virus in urban and rural population of Northeast Brazil: pilot study. Arq Gastroenterol 32: 168-171, 1995.
6. Pontello R, Reiche EMV, Inouye MMZ and Souza JLK: Freqüência de positividade dos marcadores sorológicos dos vírus de hepatite A, B e C em 500 candidatos a doadores de sangue do Hemocentro do Hospital Universitário Regional Norte do Paraná, Londrina, PR. Rev Bras Anal Clin 25: 7-10, 1993.
7. Reiche EMV, Morimoto HK, Farias GN, et al: Prevalência de tripanossomíase americana, sífilis, toxoplasmose, rubéola, hepatite B, hepatite C e da infecção pelo vírus da imunodeficiência humana, avaliada por intermédio de testes sorológicos, em gestantes atendidas no período de 1996 a 1998, no Hospital Universitário Regional Norte do Paraná. UEL, Londrina, PR, Brasil. Rev Soc Bras Med Trop 33: 519-527, 2000.
8. Haydon GH and Mutimer DJ: Hepatitis B and C virus infections in the immune compromised. Curr Opin Infect Dis 16: 473-479, 2003.
9. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC and Rezza G: Co-infection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 172: 1503-1508, 1995.
10. Fainboim H, Gonzáles J, Fassio E, et al: Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat 6: 53-57, 1999.
11. Moorman JP: Issues in HIV/Hepatitis C co-infection. Curr Infect Dis Rep 3: 131-136, 2001.
12. Rodríguez L, Collado-Mesa F, Aragón U, Díaz B and Rivero J: Hepatitis B exposure in human immunodeficiency virus sero-positive Cuban patients. Mem Inst Oswaldo Cruz 95: 243-245, 2000.
13. Carlos Martin J, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J and Soriano V: Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 5: 125-131, 2004.
14. Verucchi G, Calza L, Manfredi R and Chiodo F: Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 32: 33-46, 2004.
15. Reiche EMV, Vogler IH, Morimoto HK, et al: Evaluation of surrogate markers for human immunodeficiency virus infection among blood donors at the blood bank of Hospital Universitário Regional Norte do Paraná, Londrina, PR, Brazil. Rev Inst Med Trop Sao Paulo 45: 23-27, 2003.
16. Reiche EMV, Bonametti AM, Watanabe MAE, et al: Socio-demographic and epidemiological characteristics associated with human immunodeficiency virus type 1 (HIV-1) infection in HIV-1-exposed but uninfected individuals, and in HIV-1-infected patients from a southern Brazilian population. Rev Inst Med Trop Sao Paulo 47: 239-246, 2005.
17. Vogler IH, Nishiys A, Morimoto HK, et al: Serological, epidemiological and molecular aspects of hepatitis C virus infection in a population from Londrina, PR, Brazil, 2001-2002. Rev Inst Med Trop Sao Paulo 46: 303-308, 2004.
18. Quan CM, Krajden M, Grigoriew GA and Salit IE: Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infec Dis 17: 117-119, 1993.
19. Haydon GH, Flegg PJ, Blair CS, Brettle RP, Burns SM and Hayes PC: The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 10: 485-489, 1998.
20. + cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 40: 859-867, 2005.
21. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE and Thomas DL: Hepatitis C and progression of HIV disease. JAMA 288: 199-206, 2002.
22. Piroth L, Grappin M, Cuzin L, et al: Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hep 7: 302-308, 2000.
23. Greub G, Ledergerber B, Battegay M, et al: Clinical progression, survival, and immune recovery during anti-retroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356: 1800-1805, 2000.
24. Sabin CA, Telfer P, Phillips AN, Bhagani S and Lee CA: The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 175: 163-168, 1997.
25. Harcourt GC, Donfield S, Gomperts E, et al: Longitudinal analysis of CD8 T-cell responses to HIV and hepatitis C virus in a cohort of co-infected haemophiliacs. AIDS 19: 1135-1143, 2005.
26. Parodi C, Belmonte L, Bare P, De Bracco MM and Ruibal-Ares B: Impact of human immune deficiency virus infection on hepatitis C virus infection and replication. Curr HIV Res 5: 55-67, 2007.
27. Marins JRP, Barros MB de A, Machado H, et al: Characteristics and survival of AIDS patients with hepatitis C: Brazilian National Cohort of 1995-1996. AIDS 19: S27-S30, 2005.
28. Daar ES, Lynn H, Donfield S, et al: Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 26: 455-472, 2001.
29. Sulkwoski MS: Hepatitis C virus infection in HIV-1 infected patients. Curr Infect Dis Rep 3: 469-476, 2001.
30. + T cell count in individuals coinfected with HIV-1. Blood 105: 1170-1178, 2005.
31. UNAIDS - Joint United Nations Programme on HIV/AIDS. AIDS epidemic update: special report on HIV/AIDS: December 2006.
32. a. semanas epidemiológicas January-June, 2006. Boletim Epidemiológico AIDS 1: 3-49, 2006 (In Portuguese).
33. a. semanas epidemiológicas January-December, 2003. Boletim Epidemiológico AIDS 17, 2003 (In Portuguese).
34. Reiche EMV, Watanabe MAE, Bonametti AM, et al: Stromal cell-derived factor 1 (SDF1) genetic polymorphism in a sample of healthy individuals, seronegative individuals exposed to human immunodeficiency virus type 1 (HIV-1) and patients infected with HIV-1 from the Brazilian population. Int J Immunogenet 33: 127-133, 2006.
35. Reiche EMV, Watanabe MAE, Bonametti AM, et al: The effect of stromal cell-derived factor 1 (SDF1/CXCL12) genetic polymorphism on HIV-1 disease progression. Int J Mol Med 18: 785-793, 2006.
36. Brazil. Ministry of Health. National Coordination of Sexually Transmitted Diseases (STD) and AIDS. Recomendações para Terapia anti-retroviral em adultos e adolescentes infectados pelo HIV 2002/2003, Brasília, 2002. URL: http://www.aidsw.gov.br. Captured in 27/12/2002, 2002 (In Portuguese).
37. Brazil. Ministry of Health. National Coordination of Sexually Transmitted Diseases (STD) and AIDS. Revisão da Definição Nacional de Caso de AIDS em indivíduos com 13 anos ou mais, para fins de vigilância epidemiológica. Brasília: Ministry of Health, 1998 (In Portuguese).
38. Brazil. Ministry of Health. Agência Nacional de Vigilância Sanitária. Portaria no. 488, 17 June, 1998 (In Portuguese).
39. Morimoto HK, Caterino-de-Araújo A, Morimoto AA, et al: Seroprevalence and risk factors for human T cell lymphotropic virus type 1 and 2 infection in human immunodeficiency virus-infected patients attending AIDS referral center health units in Londrina and other communities in Paraná, Brazil. AIDS Res Hum Retroviruses 21: 256-262, 2005.
40. Fonseca MG, Szwarcwald CL and Bastos FI: Análise sociodemográfica da epidemia de Aids no Brasil, 1989-1997. Rev Saude Publica 36: 678-685, 2002.
41. Mendes-Corrêa MC, Barone AA, Cavalheiro NP, Tengan FM and Guastini C: Prevalence of hepatitis B and C in the sera of patients with HIV infection in São Paulo, Brazil. Rev Inst Med Trop Sao Paulo 42: 81-85, 2000.
42. Braga WS, Da Costa Castilho M, Dos Santos IC, Moura MA and Segurado AC: Low prevalence of hepatitis B virus, hepatitis D virus and hepatitis C virus among patients with human immunodeficiency virus or acquired immunodeficiency syndrome in the Brazilian Amazon basin. Rev Soc Bras Med Trop 39: 519-522, 2006.
43. García-Samaniego J, Soriano V, Miró JM, et al: Management of chronic viral hepatitis in HIV-infected patients: Spanish consensus conference. October 2000. HIV Clin Trials 3: 99-114, 2002.
44. Sullivan PS, Hanson DL, Teshale EH, Wotring LL and Brooks JT: Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 20: 1171-1179, 2006.
45. Tedaldi EM, Baker RK, Moorman AC, et al: Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36: 363-367, 2003.
46. Mascheretti S, Hintichsen H, Ross S, Hampe J, Folesch UR and Schreiber S: Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol 136: 328-333.
47. Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK and Watanabe MAE: Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 14: 1325-1334, 2007.
48. Haynes BF, Pantaleo G and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 271: 324-328, 1996.
49. + lymphocyte counts: immunologic and virologic characteristics. J Infect Dis 163: 959-965, 1991.
50. + T cells. Science 270: 1811-1815, 1995.
51. Mikawa AY, Tagliavini SA and Costa PI: CCR5 genotype and plasma β-chemokine concentration of Brazilian HIV-infected individuals. Braz J Med Biol Res 35: 1333-1337, 2002.
52. Cheng DM, Nunes D, Libman H, et al: Impact of hepatitis C on HIV progression in adults with alcohol problems. Alcohol Clin Exp Res 31: 829-836, 2007.
53. Bartlett JG and Gallant JE: Medical Management of HIV Infection. Johns Hopkins School of Medicine, Baltimore, MD, pp25-27, 2003.
54. Tanuri A, Caride E, Dantas MC, et al: Prevalence of mutations related to HIV-1 anti-retroviral resistance in Brazilian patients failing HAART. J Clin Virol 25: 39-46, 2002.
55. Cerqueira DM, Amorim RMS, Silva RR, Camara GNL, Brigido MM and Martins CRF: Anti-retroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 99: 877-882, 2004.
56. Eyer-Silva WA and Morgado MG: A genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality. Mem Inst Oswaldo Cruz 100: 869-873, 2005.